Clinical differences in symptomology, characteristics, and risk factors in patients with post-acute sequelae of COVID-19: an experience from a tertiary-care academic center

Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2 and has caused significant mortality and morbidity since it was first recognized in Wuhan, China in December 2019. Patients may suffer from a constellation of symptoms termed post-acute sequelae of COVID-19 (PASC) . Here we present findings of a retrospective cohort study describing the prevalence and predicting factors of patient-reported post-acute sequelae of COVID-19 (PASC). Categorical variables were summarized as frequency (percentage) and compared between vaccine status groups using Fisher’s exact test. Continuous variables were reported as median (range) and compared between the groups using Kruskal-Wallis test. All tests were two-sided with p value <0.05 considered statistically significant. Survey data from 132 patients with a median age of 45 years, 68% female, 83% Caucasian/Non-Hispanic. The most frequently reported PASC symptoms include fatigue (84.8%), dyspnea (54.5%), cognitive dysfunction (53%), myalgias (37.1%), lightheadedness or vertigo (36.4%), chest pain (34.8%), palpitations (34.8%), headaches (34.1%), arthralgias (31.8%), and unrefreshing sleep (31.1%). There is mounting evidence that supports higher prevalence of PASC in women, White/Caucasian, and middle-aged individuals. This knowledge can provide guidance to clinical practices to anticipate and support healthcare and self-care needs for patients at higher risk to developing PASC.

[1]  K. Khunti,et al.  Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study , 2022, BMJ.

[2]  Abd Moain Abu Dabrh,et al.  Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management , 2022, SN Comprehensive Clinical Medicine.

[3]  S. Schrag,et al.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. , 2022, JAMA.

[4]  A. Dror,et al.  Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients infected between March 2020 and November 2021 , 2022, medRxiv.

[5]  Abd Moain Abu Dabrh,et al.  Perception, Prevalence, and Prediction of Severe Infection and Post-acute Sequelae of COVID-19 , 2022, The American Journal of the Medical Sciences.

[6]  A. A. Abu Dabrh,et al.  Prevalence, Demographics, and Risk of Severe Acute COVID-19 , 2021, Cureus.

[7]  M. Heckman,et al.  Physician Satisfaction With Telemedicine During the COVID-19 Pandemic: The Mayo Clinic Florida Experience , 2021, Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

[8]  S. Yong Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments , 2021, Infectious diseases.

[9]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[10]  J. Borelli,et al.  COVID-19 Survivors' Reports of the Timing, Duration, and Health Impacts of Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection , 2021, medRxiv.

[11]  K. Dams-O’Connor,et al.  Postintensive Care Syndrome in Survivors of Critical Illness Related to Coronavirus Disease 2019: Cohort Study From a New York City Critical Care Recovery Clinic* , 2021, Critical care medicine.

[12]  C. Wolf,et al.  Sequelae in Adults at 6 Months After COVID-19 Infection , 2021, JAMA network open.

[13]  Christopher A. Aakre,et al.  Central Sensitization Phenotypes in Post Acute Sequelae of SARS-CoV-2 Infection (PASC): Defining the Post COVID Syndrome , 2021, Journal of primary care & community health.

[14]  K. Downes,et al.  Symptoms and Clinical Outcomes of Coronavirus Disease 2019 in the Outpatient Setting , 2021, SN Comprehensive Clinical Medicine.

[15]  B. Poyraz,et al.  Psychiatric morbidity and protracted symptoms after COVID-19 , 2020, Psychiatry Research.

[16]  C. Rhee,et al.  Duration of SARS-CoV-2 Infectivity: When is it Safe to Discontinue Isolation? , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[17]  T. Greenhalgh,et al.  Management of post-acute covid-19 in primary care , 2020, BMJ.

[18]  J. Dowds,et al.  Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection , 2020, medRxiv.

[19]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[20]  K. Khunti,et al.  Is ethnicity linked to incidence or outcomes of covid-19? , 2020, BMJ.

[21]  C. Yancy,et al.  COVID-19 and African Americans. , 2020, JAMA.